Related Experiment Video
Updated: Apr 19, 2026

06:46
Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
Published on: September 27, 2024
1.0K
Identification of physicians with unusual performance in screening colonoscopy databases: a Bayesian approach
Christian Stock1, Lorenz Uhlmann1, Michael Hoffmeister2
1Institute of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Gastrointestinal Endoscopy
|December 20, 2014
Summary
This study developed a statistical method to identify physicians with unusual adenoma detection rates (ADR) in screening colonoscopies. The approach successfully flagged underperforming physicians, aiding quality improvement in colorectal cancer screening programs.
Area of Science:
- Gastroenterology
- Public Health
- Biostatistics
Background:
- Adenoma detection rate (ADR) is a key quality indicator for screening colonoscopies.
- Identifying performance variations among physicians is crucial for quality assurance.
Purpose of the Study:
- To demonstrate a method for identifying physicians with unusual adenoma detection rates (ADR) in screening colonoscopy databases.
- To evaluate the effectiveness of a statistical approach in flagging performance outliers.
Main Methods:
- Bayesian random-effects modeling and Winsorization were used to create a robust model.
- Funnel plots were utilized for visualizing analysis steps and assessing divergence.
- Data from 422 physicians and 69,738 screening colonoscopies in Bavaria, Germany, were analyzed.
Main Results:
- The overall adenoma detection rate (ADR) was 26%.
- An initial model identified 62 physicians (15%) as potential outliers.
- A refined model confirmed 10 physicians (16% of outliers) with significantly lower than expected ADR at a 5% false discovery rate.
Conclusions:
- The statistical approach effectively identifies unusual performance in screening colonoscopy data.
- This method can aid in evaluating and enhancing the quality of colonoscopies within population-based colorectal cancer screening programs.

